Benzamide Compounds for Selective P2X3 Receptor Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current P2X3 receptor antagonists often cause side effects such as altered taste perception due to non-selective blockade of P2X2/3 receptors, leading to reduced patient compliance and effectiveness in chronic treatments.
Innovation Solution
Development of 1,3-thiazol-2-yl substituted benzamide compounds that selectively inhibit the P2X3 receptor with high selectivity over P2X2/3 receptors, providing improved pharmacokinetic profiles and metabolic stability, thereby minimizing taste disturbances.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective P2X3 receptor antagonists are used to achieve anti-nociceptive efficacy, then pain treatment effectiveness is improved, but taste perception is altered due to blockade of P2X2/3 receptors
Solution Approach 1:
The patent applies segmentation by designing compounds that selectively target specific receptor subtypes (P2X3 homomers) rather than blocking all P2X receptors. This is achieved through molecular structure optimization that creates differential affinity for P2X3-containing receptors versus P2X2/3 heteromers, allowing separation of therapeutic effect from side effects
Solution Approach 2:
The invention implements local quality by creating receptor-selective compounds with tailored molecular properties. The benzamide core structure with specific substituents (such as 1,3-thiazol-2-yl groups) provides localized interactions that confer selectivity for P2X3 over P2X2/3 receptors, enabling tissue-specific or receptor-specific action
2Ease of operation
If selective P2X3 receptor antagonists are developed to minimize taste disturbances, then patient compliance is improved, but compound complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically modifying molecular parameters of the benzamide core structure. Specific substituent patterns, molecular weight ranges, and structural features are optimized to achieve the desired selectivity profile. This includes adjusting parameters such as the nature of R1-R6 substituents, ring structures, and functional groups to balance selectivity with pharmacokinetic properties
Solution Approach 2:
The invention uses composite material principles by combining multiple structural elements into a unified molecular architecture. The compound consists of a benzamide core复合ed with heterocyclic rings (such as 1,3-thiazol-2-yl), various substituents, and stereocenters, creating a composite structure that achieves both selectivity and desirable pharmacological properties
3Object-affected harmful factors
If high selectivity for P2X3 receptor is achieved, then taste-related side effects are reduced, but metabolic stability may be compromised
Solution Approach 1:
The patent applies parameter changes by optimizing metabolic stability parameters alongside selectivity parameters. This includes adjusting molecular weight, logP values, and structural features that influence metabolic pathways. The compound design incorporates stable structural motifs (such as aromatic rings, heterocycles) that resist metabolic degradation while maintaining receptor selectivity
Solution Approach 2:
The invention converts the potential harm of high selectivity (which might lead to poor pharmacokinetic properties) into a benefit by carefully designing the molecular structure. The selective P2X3 antagonists are engineered with metabolic stability features, such as fluorinated groups, cyclic structures, and stable amide bonds, that protect against rapid metabolism while preserving receptor selectivity
Data Source
AI summary
The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.